Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab

Niklas Baumann, Christian Arndt, Judith Petersen, Marta Lustig, Thies Rösner, Katja Klausz, Christian Kellner, Miriam Bultmann, Lorenz Bastian, Fotini Vogiatzi, Jeanette H W Leusen, Renate Burger, Denis M Schewe, Matthias Peipp, Thomas Valerius

Research output: Contribution to journalArticleAcademicpeer-review

7 Downloads (Pure)

Abstract

Antibody-based immunotherapy is increasingly employed to treat acute lymphoblastic leukemia (ALL) patients. Many T-ALL cells express CD38 on their surface, which can be targeted by the CD38 antibody daratumumab (DARA), approved for the treatment of multiple myeloma. Tumor cell killing by myeloid cells is relevant for the efficacy of many therapeutic antibodies and can be more efficacious with human IgA than with IgG antibodies. This is demonstrated here by investigating antibody-dependent cellular phagocytosis (ADCP) by macrophages and antibody-dependent cell-mediated cytotoxicity (ADCC) by polymorphonuclear (PMN) cells using DARA (human IgG1) and an IgA2 isotype switch variant (DARA-IgA2) against T-ALL cell lines and primary patient-derived tumor cells. ADCP and ADCC are negatively regulated by interactions between CD47 on tumor cells and signal regulatory protein alpha (SIRPα) on effector cells. In order to investigate the impact of this myeloid checkpoint on T-ALL cell killing, CD47 and glutaminyl-peptide cyclotransferase like (QPCTL) knock-out T-ALL cells were employed. QPTCL is an enzymatic posttranslational modifier of CD47 activity, which can be targeted by small molecule inhibitors. Additionally, we used an IgG2σ variant of the CD47 blocking antibody magrolimab, which is in advanced clinical development. Moreover, treatment of T-ALL cells with all- trans retinoic acid (ATRA) increased CD38 expression leading to further enhanced ADCP and ADCC, particularly when DARA-IgA2 was applied. These studies demonstrate that myeloid checkpoint blockade in combination with IgA2 variants of CD38 antibodies deserves further evaluation for T-ALL immunotherapy.

Original languageEnglish
Article number949140
JournalFrontiers in Immunology
Volume13
DOIs
Publication statusPublished - 16 Aug 2022

Keywords

  • CD38
  • CD47
  • daratumumab
  • IgA
  • immunotherapy
  • SIRPα
  • T-cell acute lymphoblastic leukemia (T-ALL)

Fingerprint

Dive into the research topics of 'Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab'. Together they form a unique fingerprint.

Cite this